Animal-Assisted Therapy (AAT)
Evidence grade varies by use. See the breakdown on the entry. Read how the Atlas grades evidence.
The evidence base is growing and reported as promising in places, but it is limited by methodological problems severe enough to keep the overall rating low. Multiple randomized controlled trials and systematic reviews report short-term reductions in anxiety and improvements in mood across hospitalized, geriatric, and trauma-exposed populations; for dementia, a body of RCTs and an evidence-mapping review suggest AAT may ease agitation and neuropsychiatric symptoms, though effects on cognition, depression, and quality of life are not established. For PTSD, mostly small and preliminary trials report symptom reductions. For autism, reviews find most studies report positive social-interaction effects, but the studies are dominated by weak or no-treatment control groups that can inflate apparent benefit. Across indications, umbrella reviews repeatedly flag inconsistent terminology, very high between-study heterogeneity, small samples, short follow-up, and the impossibility of blinding, so causal claims remain fragile. Standardization is the central unresolved problem of the field.
Reference only. Not medical advice.
| Treatment | Grade | Notes |
|---|---|---|
| Dementia-related agitation and neuropsychiatric symptoms | 3 of 5 | Several RCTs and a 2024 evidence-mapping review report short-term reductions in agitation; effects on cognition, depression, and quality of life remain unproven and heterogeneity is high. |
| State anxiety in clinical and inpatient settings | 3 of 5 | Systematic reviews consistently find short-term anxiolytic effects across diverse populations; durability and standardized protocols are lacking. |
| PTSD symptom reduction | 2 of 5 | Mostly small, preliminary, and pilot trials in veterans and trauma survivors report improvement; sample sizes and controls are weak. Provider-directed care required. |
| Autism social and communication outcomes | 2 of 5 | Most reviewed studies report positive social-interaction effects, but reliance on no-treatment or treatment-as-usual controls can inflate effects; causal benefit not clearly established. |
| Physiological outcomes (blood pressure, stress hormones) | 1 of 5 | Within-session changes are sometimes observed, but meta-analyses find disparate, heterogeneous results and no reliable lasting physiological effect. |
What can go wrong
Generally well tolerated when handlers and animals are properly screened. Real risks are practical rather than physiological: zoonotic infection, allergy, bites or scratches, falls, and infection-control concerns in hospitals and eldercare, all of which credentialing standards exist to mitigate. Animal welfare is a live ethical concern, since the therapeutic animal cannot consent and can experience stress. People with relevant phobias, immune compromise, or animal allergies may be harmed rather than helped. AAT is a complement to, not a substitute for, evidence-based treatment of any mental-health or medical condition.
This is something to take to a clinician. The Atlas can tell you what is known about animal-assisted therapy (aat) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Animal-Assisted Therapy is a structured, goal-directed intervention in which a credentialed handler and a screened animal, most often a dog, are incorporated into a treatment plan delivered by a healthcare, education, or social-service professional. It sits inside a broader family of animal-assisted interventions defined by IAHAIO, and it is distinct from casual visiting programs and from legally protected service animals. The appeal is intuitive and ancient: animals calm people, lower social defenses, and create an easy bridge to human connection, and proponents report benefits for anxiety, dementia agitation, PTSD, and autistic social engagement. The honest picture is that the field is rich in enthusiasm and growing RCT activity but thin in methodological rigor, with chronic problems of inconsistent definitions, weak controls, small samples, and an inability to blind participants. The clinical signal for short-term calming is reported as real; the durable, mechanism-anchored claims remain unproven. Standardization is the work the field still owes itself.
A trained animal becomes a structured partner in therapy, and the calm it brings is easy to feel but hard to measure cleanly.
How it is supposed to work
Established mechanisms are partial. Structured human-animal interaction reliably produces short-term shifts in mood and arousal: touch and companionship lower self-reported stress and can reduce heart rate and blood pressure during a session, and the animal functions as a social catalyst that lowers a person's guard and eases engagement with a human therapist. Proposed but not settled mechanisms include oxytocin release during affiliative contact, downregulation of the stress-hormone axis, and attachment-based effects, all of which proponents cite but which human studies have measured inconsistently. The distinction that matters: the immediate calming and social-bridging effects are observable, while the deeper neuroendocrine story remains a hypothesis that outpaces the controlled human data.
What people get wrong
Often saidStudies prove that therapy dogs treat PTSD and autism.
ActuallyMost trials are small, short, and weakly controlled; they suggest short-term benefit but do not establish AAT as a proven treatment for these conditions.
Often saidA therapy animal is the same as a service or emotional-support animal.
ActuallyThey are legally and functionally distinct; therapy animals work in directed sessions and carry no special access rights under federal law.
Who profits, and who pushes back
Pet Partners
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
The organization describes registered therapy-animal teams as delivering measurable improvements in patient wellbeing across hospitals, eldercare, and schools.
Aubrey Fine, EdD
Fine presents AAT as a valuable complementary approach while urging the field to strengthen its research base and standardize practice.
Authors of AAI umbrella reviews (Animals, 2020)
They report that nearly all reviews complain of poor study quality, inconsistent terminology, and heterogeneity that limits firm conclusions.
Hal Herzog, PhD
Herzog argues the warm intuition that animals heal often runs ahead of the evidence, and that publication bias and weak controls inflate the apparent benefits of AAT.
Where the research comes from
Most of the published research on this comes from one place. 85% of it is from United States. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| United States | 85% |
| United Kingdom and Western Europe | 70% |
| Australia and New Zealand | 60% |
| Japan and East Asia | 45% |
| Latin America | 35% |
How we got here
The healing power attributed to animals is among the oldest documented in human medicine. In late third-millennium BC Mesopotamia, the goddess Gula, patron of healers and physicians, was depicted alongside dogs, and Sumerian and Babylonian texts treated dogs as healers whose licking of wounds carried therapeutic and sacred meaning; dog figurines were buried at her temple at Isin as votive offerings for cure. Ancient Egyptian reverence for healing animals is visible in the vast dog catacombs at Saqqara associated with Anubis. Indigenous peoples across every inhabited region, including First Nations of the Americas, Aboriginal Australians, and Pacific and Arctic communities, sustained reciprocal human-animal healing relationships in which animals were kin, guides, and participants in wellbeing rather than tools. Only much later did Europe adopt animals into institutional care, at the York Retreat in England in the 1790s, where Quaker reformers placed rabbits and poultry in the grounds for patients with mental illness. Florence Nightingale noted in Notes on Nursing (1860) that a small pet was often an excellent companion for the sick.
Long before clinical framing, animals were woven into healing across the non-Western world: the dogs of the Mesopotamian healing goddess Gula in the late third millennium BC, the dog cult of Anubis in ancient Egypt, and the reciprocal animal-kin healing relationships sustained by Indigenous peoples across the Americas, Australia, the Pacific, and the Arctic. Institutional Western use began at the York Retreat in England in the 1790s, and Florence Nightingale observed the value of small pets for the sick in 1860. The modern clinical field crystallized in the 20th century: child psychologist Boris Levinson, working in New York, described his dog Jingles as a co-therapist and coined the phrase pet therapy in the early 1960s, drawing initial ridicule from peers. Nurse Elaine Smith founded Therapy Dogs International in 1976 after watching a chaplain's golden retriever lift patients in an English hospital, and psychiatrist Michael McCulloch with his veterinarian brother William founded the Delta Foundation in Portland in 1977, later the Delta Society and today Pet Partners, which built the credentialing and research infrastructure of the field.
- c. 2100 BCMesopotamian healing goddess Gula depicted with dogs; dogs treated as healers in Sumerian and Babylonian practice.
- 1790sYork Retreat in England introduces animals into institutional care for mental illness.
- 1860Florence Nightingale notes the value of a small pet for the sick in Notes on Nursing.
- 1960sBoris Levinson describes dog-assisted child psychotherapy and coins pet therapy.
- 1976-1977Elaine Smith founds Therapy Dogs International (1976); McCulloch brothers found the Delta Foundation (1977), now Pet Partners.
How it is understood
AAT draws on a near-universal human intuition that animals soothe and connect, an intuition held across Indigenous and ancient traditions long before clinical framing. The modern field repackages this relationship into goal-directed, professional, time-limited sessions, which is a meaningful cultural shift from animal-as-kin to animal-as-clinical-instrument.
Where scholars disagree
The short-term clinical calming effect of AAT is observable and broadly reported, but the biological mechanism that would explain a lasting therapeutic effect is contested. The clinical finding and the mechanistic theory are separate claims with separate evidence levels.
Proponents and affiliative-neuroscience researchers
Affiliative human-animal contact triggers oxytocin release and downregulates the stress-hormone axis, providing a physiological basis for measurable, durable therapeutic benefit.
What it rests onSome within-session studies report reduced heart rate, blood pressure, and cortisol, and cite oxytocin rises after affiliative contact in human and animal work.
Anthrozoologist Hal Herzog and authors of AAI umbrella reviews
The neuroendocrine mechanism is not established in humans; observed physiological changes are inconsistent across studies, and weak controls, unblindable designs, and publication bias inflate the apparent effect.
What it rests onMeta-analyses report disparate, heterogeneous physiological results with no reliable lasting effect; umbrella reviews flag poor study quality and inconsistent terminology.
This disagreement is live. It has not settled.
At a glance
- Primary modality
- Most AAT uses dogs; horses (equine-assisted), cats, and small animals are also used in structured programs.
- Not a service animal
- Therapy animals have no federally protected access rights and are legally distinct from ADA service animals.
- Credentialing is voluntary
- No US federal certification exists; organizations like Pet Partners and Therapy Dogs International set voluntary standards.
- Central methodological gap
- Inconsistent terminology and unblindable, weakly controlled designs make causal effect sizes hard to trust.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Animal-Assisted Therapy (AAT). A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What people take it for. We have not catalogued the claims made for it.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.